AMD drug collaboration
MacuCLEAR and Mystic Pharmaceuticals are to collaborate on MacuCLEAR's upcoming Phase I/II trials of MC 1101 for the treatment and prevention of progression of dry age-related macular degeneration (AMD).
MacuCLEAR and Mystic Pharmaceuticals are to collaborate on MacuCLEAR’s upcoming Phase I/II trials of MC 1101 for the treatment and prevention of progression of dry age-related macular degeneration (AMD).
Mystic Pharmaceuticals produces the VeriDoser targeted, individual-use eyedropper drug delivery system, which MacuCLEAR will use as a platform to deliver doses of MC 1101.
MC 1101, which performed well in preclinical tests, has received FDA Fast Track status, allowing acceleration through the trial and approval process.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
